Mutational burden of stem cells studied to improve disease models and therapies

Researchers from the University of California have characterized the mutational burden of human induced pluripotent stem cells (iPSCs), potentially improving researchers’ ability to prioritize stem cell lines for models of human disease and/or therapies.

© nobeastsofierce/Shutterstock.com

Human iPSCs, which have the potential to differentiate into any type of human body cell, are widely studied by researchers, but a full understanding of their mutational burden is lacking.

These stem cells are reprogrammed from bodily tissues, including skin cells that can acquire many non-inherited (somatic) mutations as a result of exposure the sun and UV light.

Although researchers have previously identified and characterized some somatic mutations in iPSCs, there is still not a full understanding of their mutational burden, even though more than 1,000 iPSC lines have been developed globally.

As reported in the journal Cell Reports, Kelly Frazer and colleagues have now identified and characterized somatic mutations in 18 iPSC lines derived from reprogrammed skin cells using whole-genome sequencing, transcriptome and epigenome data.

"Induced pluripotent stem cells represent a huge opportunity for science and medicine, but to truly and effectively use them we need to more completely understand their mutational burden. If we can detect somatic mutations for each iPSC line on an individual basis, we can use that information to prioritize iPSC lines for models of specific human diseases and/or transplantation therapies," says Frazer.

As well managing to further characterize two classes of somatic mutations, the team also found two new classes, one being mutations in the parental cell caused by UV damage and the other being subclonal mutations that were not in the parental cell, but arose during reprogramming.

Importantly, the team found that although most of the mutations occurred in epigenetic regions associated with closed chromatin and did not influence gene expression, the subclonal mutations that arose through reprogramming demonstrated a greater association with active chromatin and did alter gene expression.

Source:

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2018, August 23). Mutational burden of stem cells studied to improve disease models and therapies. News-Medical. Retrieved on December 19, 2024 from https://www.news-medical.net/news/20180725/Mutational-burden-of-stem-cells-studied-to-improve-disease-models-and-therapies.aspx.

  • MLA

    Robertson, Sally. "Mutational burden of stem cells studied to improve disease models and therapies". News-Medical. 19 December 2024. <https://www.news-medical.net/news/20180725/Mutational-burden-of-stem-cells-studied-to-improve-disease-models-and-therapies.aspx>.

  • Chicago

    Robertson, Sally. "Mutational burden of stem cells studied to improve disease models and therapies". News-Medical. https://www.news-medical.net/news/20180725/Mutational-burden-of-stem-cells-studied-to-improve-disease-models-and-therapies.aspx. (accessed December 19, 2024).

  • Harvard

    Robertson, Sally. 2018. Mutational burden of stem cells studied to improve disease models and therapies. News-Medical, viewed 19 December 2024, https://www.news-medical.net/news/20180725/Mutational-burden-of-stem-cells-studied-to-improve-disease-models-and-therapies.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
TTUHSC researcher to uncover mechanisms that regulate gene expression in Alzheimer's disease